Osugi Jun, Owada Yuki, Yamaura Takumi, Muto Satoshi, Okabe Naoyuki, Matsumura Yuki, Higuchi Mitsunori, Suzuki Hiroyuki, Gotoh Mitsukazu
Department of Regenerative Surgery, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Case Rep Oncol. 2016 Jan 15;9(1):51-5. doi: 10.1159/000443662. eCollection 2016 Jan-Apr.
Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event. In such cases, interruption and dose reduction of crizotinib might be necessary for some patients with severe neutropenia. However, information concerning clinical experience and management of severe neutropenia is currently limited. In this report, the successful management of crizotinib-induced neutropenia by dose reduction of crizotinib in a patient with ALK-positive non-small cell lung cancer is described.
克唑替尼是首个可临床应用的间变性淋巴瘤激酶（ALK）基因重排抑制剂，一般耐受性良好。相比之下，克唑替尼诱导的中性粒细胞减少是一种常见报道的3级或4级不良事件。在这种情况下，对于一些严重中性粒细胞减少的患者，可能有必要中断克唑替尼治疗并减少剂量。然而，目前关于严重中性粒细胞减少的临床经验和管理的信息有限。本报告描述了一名ALK阳性非小细胞肺癌患者通过减少克唑替尼剂量成功管理克唑替尼诱导的中性粒细胞减少的情况。
